<- Go Home
Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Market Cap
$21.5M
Volume
222.5K
Cash and Equivalents
$3.7M
EBITDA
-$9.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.86
52 Week Low
$3.10
Dividend
N/A
Price / Book Value
5.47
Price / Earnings
-4.29
Price / Tangible Book Value
-5.05
Enterprise Value
$17.9M
Enterprise Value / EBITDA
-1.89
Operating Income
-$10.1M
Return on Equity
92.47%
Return on Assets
-43.46
Cash and Short Term Investments
$3.7M
Debt
$176.0K
Equity
$3.9M
Revenue
N/A
Unlevered FCF
-$4.2M
Sector
Biotechnology
Category
N/A